Landos Biopharma, Inc.
PLXDC2 ligands
Last updated:
Abstract:
Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
Status:
Grant
Type:
Utility
Filling date:
25 Mar 2021
Issue date:
23 Nov 2021